In a significant step towards tackling one of the UK’s most underdiagnosed conditions, North East and North Cumbria Integrated Care Board (ICB) has adopted the Healthinote digital health platform, ...

Boehringer Ingelheim announces the start of the THULITE Phase II clinical study. It will investigate the efficacy, safety and tolerability of BI 1815368 as a potential oral treatment to improve vision ...

DelveInsight’s Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline ...

North East and North Cumbria NHS has begun a year-long rollout of the Healthinote digital health platform to support patients ...

Pioneer in RNA research who gave children with SMA a future Sabine Löwer Communications Boehringer Ingelheim St ...

In a significant push to address one of the Philippines’ most pressing but underrecognized public health issues, the German-Philippine Chamber of Commerce and Industry (GPCCI), the German Embassy ...

Boehringer Ingelheim & LEO Pharma partner to commercialize and further develop Spevigo: Ingelheim, Germany Wednesday, July 16, 2025, 15:00 Hrs [IST] Boehringer Ingelheim, a biopha ...

Boehringer Ingelheim and SoundTalks end their partnership, but what does this mean for pig farmers? Find out about the future ...

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.

BI 1815368, a potential oral treatment to improve vision in patients with diabetic macular edema, is being investigated in a ...

LEO Pharma acquires global rights to Spevigo for $105M, boosting its dermatology pipeline and expanding access for patients ...